Back to top
more

Owens & Minor (OMI)

(Delayed Data from NYSE)

$14.58 USD

14.58
372,349

-0.20 (-1.35%)

Updated Oct 3, 2024 04:00 PM ET

After-Market: $14.58 0.00 (0.00%) 4:54 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 19% (49 out of 252)

Industry: Medical - Products

Better trading starts here.

Zacks News

Owens & Minor (OMI) Dips More Than Broader Markets: What You Should Know

Owens & Minor (OMI) closed at $33.41 in the latest trading session, marking a -2.62% move from the prior day.

Zimmer Biomet's (ZBH) Recovery to Continue Despite Pandemic

Zimmer Biomet's (ZBH) spin-off decision of the non-core dental and spine business is expected to prove strategic.

Owens & Minor (OMI) Moves to Strong Buy: Rationale Behind the Upgrade

Owens & Minor (OMI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

New Strong Buy Stocks for May 7th

CBT, OMI, ARCB, BWFG, and NVST have been added to the Zacks Rank #1 (Strong Buy) List on May 7, 2021.

Kinjel Shah headshot

6 Low Price-to-Book Value Stocks to Buy in May

P/B ratio is emerging as a convenient tool to identify low-priced stocks that have high-growth prospects.

National Vision (EYE) to Report Q1 Earnings: What's in Store?

National Vision's (EYE) transitions of five additional Walmart Vision Centers in 2020, which have become operative of late, are expected to post positive Q1 results.

GoodRx (GDRX) to Report Q1 Earnings: What's in the Offing?

GoodRx' (GDRX) manufacturer solutions offerings continue to grow at a strong rate, registering record bookings over the past months.

Owens & Minor (OMI) Surpasses Q1 Earnings and Revenue Estimates

Owens & Minor (OMI) delivered earnings and revenue surprises of 61.86% and 1.55%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

4 Medical Products Stocks Set to Beat This Earnings Season

Rebound in base sales make us optimistic about OMI, INGN, XRAY and CNTG's results this time around.

DENTSPLY SIRONA (XRAY) to Post Q1 Earnings: What's in Store?

DENTSPLY SIRONA's (XRAY) first-quarter results are likely to reflect weak segmental performance.

Merit Medical (MMSI) Q1 Earnings and Revenues Beat Estimates

Merit Medical (MMSI) benefits from growth in revenues at the Cardiovascular segment in Q1.

DaVita (DVA) Q1 Earnings Beat Estimates, Revenues Miss Mark

DaVita's (DVA) net dialysis and related lab-patient service revenues rise in Q1.

Omnicell (OMCL) Q1 Earnings Beat Estimates, Margins Expand

Omnicell's (OMCL) raises adjusted EPS guidance for 2021 , which buoys optimism.

DexCom (DXCM) Q1 Earnings and Revenues Surpass Estimates

DexCom's (DXCM) first-quarter results benefit from domestic and international revenue growth.

Teleflex (TFX) Beats on Q1 Earnings and Revenues, Raises View

The acquisition of Z-Medica and an increase in sales of new products contribute to Teleflex's (TFX) revenue growth in Americas in Q1

ABIOMED (ABMD) Earnings and Revenues Beat Estimates in Q4

ABIOMED's (ABMD) international and U.S. Impella revenues improve in Q4.

Surmodics (SRDX) Q2 Earnings Beat Estimates, Revenues Miss

Surmodics (SRDX) records higher revenues in both its core units in the fiscal second quarter.

Is Owens & Minor (OMI) a Great Value Stock Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

CONMED (CNMD) Earnings and Revenue Surpass Estimates in Q1

CONMED (CNMD) witnesses growth in revenues in both its segments during Q1.

LabCorp (LH) Q1 Earnings Surpass Estimates, View Raised

LabCorp's (LH) raises 2021 guidance but projects significant sinking of COVID-related testing revenues.

Hologic (HOLX) Q2 Earnings Miss Estimates, Margins Rise

Hologic (HOLX) exhibited robust segmental growth in second-quarter fiscal 2021, driven by strong performance by the Diagnostics segment amid the coronavirus pandemic.

Amedisys (AMED) Q1 Earnings Beat Estimates, 2021 View Up

Amedisys' (AMED) first-quarter 2021 revenues improves year over year on solid growth in the Home Health and Hospice divisions.

OPKO Health (OPK) Q1 Earnings Match Estimates, Revenues Top

OPKO Health's (OPK) first-quarter results benefit from strength in diagnostics.

Integra (IART) Q1 Earnings Beat Estimates, Gross Margin Down

Integra's (IART) first-quarter revenues improved year over year on organic growth across Codman Specialty Surgical and Tissue Technologies segments.

Baxter (BAX) Q1 Earnings and Revenues Surpass Estimates

Baxter's (BAX) first-quarter results reflect robust performance across five of its business units.